Presented in abstract form at the 30th Annual Conference of the Veterinary Cancer Society, San Diego, CA, USA, October 2010.
Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours†
Article first published online: 1 JUN 2011
© 2011 Blackwell Publishing Ltd
Veterinary and Comparative Oncology
Special Issue: Tyrosine kinase inhibitors
Volume 10, Issue 3, pages 194–205, September 2012
How to Cite
London, C., Mathie, T., Stingle, N., Clifford, C., Haney, S., Klein, M. K., Beaver, L., Vickery, K., Vail, D. M., Hershey, B., Ettinger, S., Vaughan, A., Alvarez, F., Hillman, L., Kiselow, M., Thamm, D., Higginbotham, M. L., Gauthier, M., Krick, E., Phillips, B., LaDue, T., Jones, P., Bryan, J., Gill, V., Novasad, A., Fulton, L., Carreras, J., McNeill, C., Henry, C. and Gillings, S. (2012), Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours. Veterinary and Comparative Oncology, 10: 194–205. doi: 10.1111/j.1476-5829.2011.00275.x
- Issue published online: 6 AUG 2012
- Article first published online: 1 JUN 2011
The purpose of this study was to provide an initial assessment of the potential biologic activity of toceranib phosphate (Palladia®, Pfizer Animal Health, Madison, NJ, USA) in select solid tumours in dogs. Cases in which toceranib was used to treat dogs with apocrine gland anal sac adenocarcinoma (AGASACA), metastatic osteosarcoma (OSA), thyroid carcinoma, head and neck carcinoma and nasal carcinoma were included. Clinical benefit (CB) was observed in 63/85 (74%) dogs including 28/32 AGASACA [8 partial response (PR), 20 stable disease (SD)], 11/23 OSAs (1 PR and 10 SD), 12/15 thyroid carcinomas (4 PR and 8 SD), 7/8 head and neck carcinomas [1 complete response (CR), 5 PR and 1 SD] and 5/7 (1 CR and 4 SD) nasal carcinomas. For dogs experiencing CB, the median dose of toceranib was 2.8 mg kg−1, 36/63 (58.7%) were dosed on a Monday/Wednesday/Friday basis and 47/63 (74.6%) were treated 4 months or longer. Although these data provide preliminary evidence that toceranib exhibits CB in dogs with certain solid tumours, future prospective studies are necessary to define its true activity.